What viscosupplementation actually does inside the knee

Healthy knee joints are lined with synovial fluid — a thick, slippery substance that acts as both lubricant and shock absorber. One of its key ingredients is hyaluronic acid (HA), a naturally occurring molecule that gives synovial fluid its characteristic viscosity. In osteoarthritis, the concentration and quality of HA in the joint gradually declines, leaving the fluid thinner and less effective at protecting cartilage surfaces during movement and load-bearing.

Viscosupplementation is the clinical term for injecting a manufactured HA solution directly into the knee joint to restore some of that lost cushioning and lubrication. The goal is mechanical: to supplement what the joint is no longer producing adequately, reducing friction between the joint surfaces.

It is worth distinguishing this from other common knee injections. Corticosteroids act primarily by suppressing inflammation. Platelet-rich plasma (PRP) and other biologic treatments aim to influence tissue repair processes. HA injections work differently — their principal role is physical, restoring the environment inside the joint rather than targeting inflammation or stimulating tissue regeneration directly.

Depending on the product used, a course of viscosupplementation involves one to three injections administered by a clinician under sterile conditions, typically spaced a week apart for multi-injection regimens.

Why the guidelines do not agree — and what that means for you

Depending on which clinician you ask — or which country's guidelines they follow — you may receive strikingly different advice about HA injections. That disagreement is real, and it is worth understanding why.

The two most influential bodies in the UK context, NICE and the American Academy of Orthopaedic Surgeons (AAOS), conditionally recommend against routine use. A February 2026 analysis in Australian Prescriber went further, concluding that randomised controlled trial evidence shows no clinically important benefit and identifying potentially serious harms including septic arthritis and severe inflammatory reactions — a notable cautionary signal from a peer-reviewed prescribing journal.

At the same time, a 2026 network meta-analysis drawing on 43 trials and approximately 5,500 patients found that HA produced a meaningful average pain reduction compared with placebo, with a low rate of adverse events. European bodies — OARSI, ESCEO, and especially the EUROVISCO panel — conditionally to strongly endorse viscosupplementation, particularly for specific patient profiles.

Much of the divergence traces to a methodological problem: most large pooled analyses combine products with very different molecular weights and injection regimens as though they were interchangeable. That pooling may dilute real differences between formulations and obscure which patients actually benefit.

In practice, a UK patient may find their GP — following NICE guidance — advises against HA, while an orthopaedic or sports-medicine specialist referencing international consensus is willing to offer it. Neither position represents negligence or confusion; both reflect legitimate readings of an incomplete evidence base. The honest answer is that the science has not yet resolved the question for everyone — which is why patient selection matters so much, a point the next section addresses directly.

The patients most likely to benefit

Patient selection is where the clinical case for HA injections is strongest — and the evidence here is more consistent than the guideline disagreement might suggest.

The clearest candidates are people with mild-to-moderate knee osteoarthritis, typically corresponding to Kellgren–Lawrence grades II or III on imaging — meaning joint space is narrowed but not lost, and cartilage damage has not reached bone-on-bone contact. Crucially, HA sits after conservative care in the treatment pathway, not before it. Clinicians generally consider it once physiotherapy, weight management, activity modification, and simple analgesia have been tried and have not provided adequate relief.

A structured expert agreement — developed by a panel of 12 specialists across multiple rounds of review and published as the EUROVISCO Delphi consensus in 2024–2025 — provides the most clinically specific guidance on suitable patients. It explicitly endorses HA regardless of the patient's age, and supports its use in people with type 1 or 2 diabetes, moderate-to-severe obesity, and a history of stable gout or calcium crystal deposits in the joint. The common thread is that these are populations for whom prolonged use of oral NSAIDs — the usual alternative — carries meaningful cardiovascular or gastrointestinal risk.

That is arguably the strongest clinical argument for HA: even a modest reduction in pain is clinically worthwhile when the oral alternatives are genuinely unsafe for that individual. Mild-to-moderate varus or valgus malalignment of the knee does not exclude candidacy according to the same consensus, though severe end-stage disease or extreme malalignment significantly reduces the likelihood of benefit.

When HA is unlikely to help or should be avoided

Screening for factors that reduce the chance of a useful response is a routine part of any pre-injection assessment, and being aware of them helps patients ask the right questions.

Hard contraindications — situations where HA should not be given — include an active infection in or around the joint, a systemic infection anywhere in the body, known allergy to hyaluronic acid or to avian-derived products, and pregnancy. The EUROVISCO consensus also strongly advises against injecting during an acute inflammatory flare; the standard approach is to settle the flare first, then revisit viscosupplementation once inflammation has subsided.

Structural factors matter too. Severe, end-stage disease — Kellgren–Lawrence grade IV, where cartilage is largely gone and bone is contacting bone — is generally expected to produce little or no meaningful response. At that stage, a surgical opinion is more appropriate than repeated injection courses.

Predictors of shorter benefit duration are worth discussing with your clinician even when HA is otherwise suitable. A cross-sectional study of 105 patients and 149 knees found the average benefit lasted around 48 weeks — but that duration shortened significantly in people with a BMI above 27.5 kg/m², involvement of more than one knee compartment, more than three prior injection courses, or a sedentary lifestyle. None of these factors is an absolute bar, but they do indicate the benefit may be more modest or less sustained — and that sets realistic expectations from the outset.

Formulation, dosing, and what to expect from a course

Not all HA products are the same — and this catches many patients off-guard when they discover a friend received a different number of injections, or an apparently different type of product. The key variable is molecular weight (MW): HA molecules come in different sizes, and size influences both how long the product remains active in the joint and how the tissue responds to it.

Real-world data from a 15-year cohort following more than 2,000 knee OA patients provides the most direct comparison available. Among those who initially responded to treatment, very-high-molecular-weight HA maintained a sustained response in around 85% of cases, compared with approximately 67% for high-molecular-weight HA — a clinically meaningful difference in durability over the longer term.

Single injection or a course?

Some HA formulations are designed for a single injection; others are given as three weekly injections. A cross-linked high-molecular-weight product administered as a single dose appears to produce equivalent pain relief and functional improvement at both two and six months compared with a three-injection course of a linear low-molecular-weight product. For most patients, the choice comes down to convenience rather than a difference in outcome.

What to expect — and when

HA is not a rapid pain reliever in the way a corticosteroid injection is. Response tends to build over several weeks, and some patients do not notice the full effect until four to eight weeks after the injection — so early impatience is understandable but not necessarily a sign that treatment has failed.

If the initial course works, repeat treatment is generally feasible every six to twelve months. Before each injection, any excess fluid in the joint is typically drained first; combining HA with a corticosteroid in the same syringe is generally discouraged.

How HA compares to other injection options on cost and evidence

Cost matters — and for a UK patient weighing up injection options, the published health-economics data on HA is broadly reassuring. A 2025 analysis using the validated OAPol model estimated HA's incremental cost per quality-adjusted life year gained at approximately £17,000–£42,000 (converted from US dollar figures; exchange rates mean this is an approximation). Both figures sit within the range that health economists typically regard as cost-effective, making HA comparatively good value among the available injection therapies.

For context, the same modelling estimated that platelet-rich plasma (PRP) cost roughly £87,000 per QALY gained versus HA — above the thresholds usually applied in the UK. That does not mean PRP has no place; some patients respond well, and the evidence base continues to evolve. The point is relative positioning, not a verdict against PRP.

Combination approaches — pairing HA with PRP or chondroitin sulfate — and newer hybrid HA formulations that use mannitol or sorbitol to extend joint residence time are generating early 2025–2026 evidence, but they have not yet reached mainstream guideline recommendations.

HA also occupies a specific rung in the treatment pathway: it follows exercise and physiotherapy, not replaces them. When joint damage becomes severe and repeated injection courses are no longer providing meaningful relief, the appropriate next step is a surgical assessment — whether joint-preservation procedures or, where indicated, knee replacement.

A specialist assessment is the right point at which to weigh these options against an individual patient's imaging, symptoms, and priorities.

1. [1] Intra-Articular Hyaluronic Acid for Knee Osteoarthritis: A Systematic Umbrella Review (JCM 2025). (2025). https://doi.org/10.3390/jcm14041272 https://doi.org/10.3390/jcm14041272
2. [2] EUROVISCO Consensus Guidelines for the Use of Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis Based on Patient Characteristics. (2024). https://doi.org/10.1177/19476035241271970 https://doi.org/10.1177/19476035241271970
3. [3] Cross-sectional study of factors predicting the duration of efficacy of viscosupplementation in knee OA. (2024). https://doi.org/10.3390/jcm13071949 https://doi.org/10.3390/jcm13071949
4. [4] Long-term sustained benefits of viscosupplementation with different MW hyaluronic acids in knee OA (HAV-OAK, 15-year cohort). (2025). https://doi.org/10.1302/1358-992x.2025.13.122 https://doi.org/10.1302/1358-992x.2025.13.122
5. [5] Intra-articular injections for knee OA management: analysis of cost-effectiveness (Osteoarthritis and Cartilage Reports 2025). (2025). https://doi.org/10.1016/j.ocarto.2025.100641 https://doi.org/10.1016/j.ocarto.2025.100641